REGENECYTE not checked

StemCyte, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome, Post-COVID Condition
Main trialPhase 3
“REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.”In the company’s words, NCT07184385 on ClinicalTrials.gov

Other drugs for Long COVID

All 7 drugs for Long COVID

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Jun 2027 A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
Phase 2Completed 26 Jul 2024 Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow REGENECYTE

Following is part of Solo: you see every change to REGENECYTE the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in